vancomycin has been researched along with ketoconazole in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghatabay, NM; Dülger, B; Haciu, D; Karabiyik, T; Neshat, A; Somer, M | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Aghatabay, NM; Dulger, B; Gucin, F; Senel, M; Somer, M | 1 |
| Aghatabay, NM; Cevik, H; Dulger, B; Mahmiani, Y | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Aghatabay, NM; Baş, A; Dülger, B; Gücin, F; Kircali, A; Sen, G; Yazicioğlu, MB | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Aytemir, MD; Ozçelik, B | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bao, L; Cai, L; Chen, JL; Huang, P; Liu, HW; Liu, MM; Qi, QY; Wang, QX; Yang, JL; Yang, XL; Zhang, LX | 1 |
| Cai, G; Cho, S; Franzblau, SG; Jaki, BU; Lee, IA; McAlpine, JB; Napolitano, JG; Pauli, GF; Suh, JW; Wang, Y; Yang, SH | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Hu, L; Lan, L; Li, B; Li, J; Li, X; Lin, D; Liu, W; Liu, Y; Lu, Y; Mao, F; Ni, S; Qiu, X; Wang, M; Wei, H; Xu, Y; Zheng, X; Zhu, J | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Bercy, P; De Beule, F; Ferrant, A | 1 |
| Beatty, DW; Daubenton, JD | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for vancomycin and ketoconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for vancomycin and ketoconazole
| Article | Year |
|---|---|
Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cadmium; Chelating Agents; Disk Diffusion Antimicrobial Tests; Ferrous Compounds; Ligands; Magnetic Resonance Spectroscopy; Metals, Heavy; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Organomercury Compounds; Organometallic Compounds; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Structure-Activity Relationship; Zinc | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.
Topics: Anti-Infective Agents; Bacteria; Disk Diffusion Antimicrobial Tests; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Organometallic Compounds; Palladium; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spectrum Analysis, Raman; Yeasts | 2007 |
Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.
Topics: Anti-Infective Agents; Aza Compounds; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Ligands; Macrocyclic Compounds; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spectrum Analysis, Raman | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Apoptosis; Bacteria; Cattle; Cell Line, Tumor; DNA; Humans; Macrocyclic Compounds; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Yeasts | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Bacteria; Cell Line; Chlorocebus aethiops; Drug Evaluation, Preclinical; Fungi; Herpesvirus 1, Human; Mannich Bases; Microbial Sensitivity Tests; Parainfluenza Virus 3, Human; Pyrones; Spectrum Analysis; Vero Cells | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
3-Anhydro-6-hydroxy-ophiobolin A, a new sesterterpene inhibiting the growth of methicillin-resistant Staphylococcus aureus and inducing the cell death by apoptosis on K562, from the phytopathogenic fungus Bipolaris oryzae.
Topics: Apoptosis; Cell Death; Drug Screening Assays, Antitumor; Flow Cytometry; Hep G2 Cells; Humans; K562 Cells; Methicillin-Resistant Staphylococcus aureus; Oryza; Sesterterpenes; Structure-Activity Relationship | 2013 |
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Peptides, Cyclic; Streptomyces; Vero Cells | 2013 |
Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Drug Resistance, Bacterial; Ether-A-Go-Go Potassium Channels; Linezolid; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Staphylococcal Infections; Structure-Activity Relationship; Vancomycin; Vancomycin Resistance; Xanthophylls | 2017 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
The effectiveness of a preventive regimen on the periodontal health of patients undergoing chemotherapy for leukemia and lymphoma.
Topics: Acyclovir; Amphotericin B; Ceftazidime; Chlorhexidine; Dental Plaque Index; Fluconazole; Humans; Immunosuppression Therapy; Ketoconazole; Leukemia; Lymphoma; Miconazole; Norfloxacin; Periodontal Diseases; Periodontal Index; Tooth Loss; Vancomycin | 1991 |
Disseminated histoplasmosis in an 'immunocompetent' child.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Child; Histoplasma; Histoplasmosis; Humans; Immunocompetence; Itraconazole; Ketoconazole; Male; Vancomycin | 1998 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |